Akeso Biotech sank 22% to HKD 64.10 today, primarily driven by FDA's rejection of ivonescimab, a lung cancer drug developed with partner Summit Therapeutics, for U.S. market approval. The stock plunged to HKD 56.10 during intraday trading, marking a fresh 52-week low, before buyers returned to lift it to HKD 64.85 by afternoon's end. Citi and Nomura subsequently cut their target prices to HKD 163 and HKD 94 respectively, reflecting market reassessment of this clinical setback. Positively, gumokimab secured regulatory approval in China for active ankylosing spondylitis, and recent quarters demonstrated revenue growth surpassing 35%. Nevertheless, the company remains unprofitable, with Q2 posting a net loss of HKD 244.9 million. From a price-position perspective, the stock has tumbled 43.42% since year-start and trades 59% below its 52-week peak of HKD 156, having recovered only 14% from yesterday's 52-week nadir, signaling fragile investor sentiment.